Results 111 to 120 of about 49,721 (234)

Chaetocin Induces Ferroptosis in Cisplatin‐Resistant Ovarian Cancer Cells Through Neddylation‐Mediated TFRC Upregulation

open access: yesPhytotherapy Research, EarlyView.
Chaetocin induces ferroptosis in cisplatin‐resistant ovarian cancer cells through neddylation‐mediated TFRC upregulation. ABSTRACT Ovarian cancer (OV) is a highly lethal gynecological tumor, often developing platinum chemotherapy resistance and treatment failure.
Hanfei Xie   +5 more
wiley   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

open access: yesVIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf   +5 more
wiley   +1 more source

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

open access: yesInternational Journal of Nanomedicine, 2013
Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women.
Gupta N, Hatoum H, Dy GK
doaj  

Angiogenesis‐associated immune genes as prognostic markers and predictors of immunotherapy response in pancreatic ductal adenocarcinoma

open access: yesVIEW, EarlyView.
Pancreatic ductal adenocarcinoma exhibits marked angiogenic and immune heterogeneity. We identified 28 angiogenesis‐associated immune genes and developed a seven‐gene AIGScore model comprising FGF2, ADGRB3, MMP2, TYMP, VASH1, VEGFD, and ITGAV. A high AIGScore was associated with poor survival, an immunosuppressive tumor microenvironment, and reduced ...
Qing Chang   +4 more
wiley   +1 more source

Current Advances of Treatments, Therapeutic Targets, Biomarkers, Novel Drugs, and Machine Learning for Hypopharyngeal Squamous Cell Carcinoma

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Hypopharyngeal squamous cell carcinoma (HSCC) is an aggressive subtype of head and neck squamous cell carcinoma with insidious onset, early metastasis, and dismal prognosis. Conventional multimodal therapy achieves limited survival benefit, highlighting an urgent need for refined precision strategies.
Ce Li   +12 more
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

open access: yesAllergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud   +14 more
wiley   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

open access: yesAndrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis   +3 more
wiley   +1 more source

Cancer pain: current practice and emerging targets

open access: yesBritish Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye   +5 more
wiley   +1 more source

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.

open access: yes, 2016
In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based paclitaxel. The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of ...
Untch, Michael;Jackisch, Christian;Schneeweiss, Andreas;Conrad, Bettina;Aktas, Bahriye;Denkert, Carsten;Eidtmann, Holger;Wiebringhaus, Hermann;Kümmel, Sherko;Hilfrich, Jörn;Warm, Mathias;Paepke, Stefan;Just, Marianne;Hanusch, Claus;Hackmann, John;Blohmer, Jens-Uwe;Clemens, Michael;Darb-Esfahani, Silvia;Schmitt, Wolfgang Daniel;Dan Costa, Serban;Gerber, Bernd;Engels, Knut;Nekljudova, Valentina;Loibl, Sibylle;von Minckwitz, Gunter
core   +1 more source

Ischaemic stroke and 5‐fluorouracil or capecitabine: A systematic review and meta‐analysis of harms and a retrospective study of the WHO pharmacovigilance database

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy